Large-scale testing (Phase 3)Study completedNCT04449861What this trial is testingDurvalumab Plus Chemotherapy in ES-SCLC (Oriental)Who this might be right forSmall Cell Lung Carcinoma Extensive Disease AstraZeneca 166
Testing effectiveness (Phase 2)Study completedNCT02705820What this trial is testingSwitch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet ChemotherapyWho this might be right forMetastatic Non Small Cell Lung Cancer Bank of Cyprus Oncology Centre 48
Large-scale testing (Phase 3)Study completedNCT01839773What this trial is testingPhase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric CancerWho this might be right forStage IV Gastric Cancer Daehwa Pharmaceutical Co., Ltd. 238
Testing effectiveness (Phase 2)Study completedNCT00828841What this trial is testingPhase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLCWho this might be right forNon-Small Cell Lung Cancer Accelerated Community Oncology Research Network 601
Large-scale testing (Phase 3)Looking for participantsNCT05058651What this trial is testingEvaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the LungWho this might be right forAdvanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more National Cancer Institute (NCI)
Large-scale testing (Phase 3)Study completedNCT01168973What this trial is testingChemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based ChemotherapyWho this might be right forNon-Small Cell Lung Cancer Eli Lilly and Company 1,253
Testing effectiveness (Phase 2)Ended earlyNCT02564380What this trial is testingStudy of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)Who this might be right forMetastatic Squamous Non-small Cell Lung Cancer AIO-Studien-gGmbH 41
Large-scale testing (Phase 3)Active Not RecruitingNCT01844986What this trial is testingOlaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.Who this might be right forNewly DiagnosedAdvanced Ovarian CancerFIGO Stage III-IV+4 more AstraZeneca 450
Large-scale testing (Phase 3)Ended earlyNCT03631199What this trial is testingStudy of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC SubjectsWho this might be right forNon-small Cell Lung Cancer Novartis Pharmaceuticals 673
Testing effectiveness (Phase 2)Study completedNCT02610140What this trial is testingPhase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)Who this might be right forMesothelioma Bayer 248
Not applicableStudy completedNCT05366725What this trial is testingLearn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After ChemotherapyWho this might be right forUrothelial Cancer Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany 106
Testing effectiveness (Phase 2)Study completedNCT00397293What this trial is testingStudy of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung CancerWho this might be right forSmall Cell Lung Cancer Ascenta Therapeutics 36
Testing effectiveness (Phase 2)Study completedNCT03427814What this trial is testingStudy of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric CancerWho this might be right forAdvanced or Inoperable Gastric Cancer BeiGene 136
Testing effectiveness (Phase 2)Study completedNCT01136031What this trial is testingPaclitaxel and Irinotecan in Advanced Gastric CancerWho this might be right forAdvanced Gastric Cancer Seoul National University Hospital 42
Testing effectiveness (Phase 2)Study completedNCT01186861What this trial is testingPhase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based ChemotherapyWho this might be right forNon-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy Astellas Pharma Inc 205
Testing effectiveness (Phase 2)Active Not RecruitingNCT04836728What this trial is testingPhase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung CancerWho this might be right forNon-small Cell Lung Cancer MetastaticFirst-line Treatment Tianjin Medical University Cancer Institute and Hospital 156
Not applicableLooking for participantsNCT06087783What this trial is testingPROtein, Leucine and Vitamin D Supplementation In Patients With GYnecologic Cancer Receiving Platinum-based ChemotherapyWho this might be right forGynecologic Cancer Fondazione IRCCS Policlinico San Matteo di Pavia 50
Testing effectiveness (Phase 2)Looking for participantsNCT06869473What this trial is testingCetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.Who this might be right forHead and Neck Squamous Cell Carcinoma (HNSCC)Recurrent Head and Neck CancerMetastatic Head and Neck Cancer Gruppo Oncologico del Nord-Ovest 67
Large-scale testing (Phase 3)UnknownNCT02738346What this trial is testingSCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013Who this might be right forSmall Cell Lung Cancer University Hospital, Angers 164
Testing effectiveness (Phase 2)UnknownNCT04755868What this trial is testingTalazoparib Maintenance Therapy in Triple-negative Breast CancerWho this might be right forTNBC - Triple-Negative Breast Cancer Yonsei University 206